Trials / Completed
CompletedNCT01820715
A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain
A Phase I Study of the DA-3030 Injection to Evaluate Its Safety and Explore the Efficacy for Diabetic Neuropathic Pain
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Dong-A Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 600㎍ of DA-3030 Injection | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2013-04-01
- First posted
- 2013-03-29
- Last updated
- 2013-08-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01820715. Inclusion in this directory is not an endorsement.